NAMS
NewAmsterdam Pharma Company N.V. (NAMS) reported net income of -$203.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$203.00M | +16.1% |
| FY 2024 | -$242.00M | -36.7% |
| FY 2023 | -$177.00M | -682.0% |
| FY 2022 | -$22.63M | +45.8% |
| FY 2021 | -$41.78M | - |
NewAmsterdam Pharma Company N.V. (NAMS) reported net income of -$203.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2021 and fiscal 2025, NewAmsterdam Pharma Company N.V.'s net income declined from -$41.78M to -$203.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.